Diabetes is characterized by poor circulation and impaired angiogenesis, which appear to contribute to the frequent skin lesions and poor wound healing common in diabetic patients. Therapies to improve circulation commonly improve wound healing in diabetic patients. Administration of circulating CD34+ cells, cells that can function as endothelial cell progenitors, accelerates blood flow restoration to ischemic limbs of diabetic mice. We have investigated the potential of these cells to accelerate revascularization and healing in full-thickness skin wounds of hypoinsulinemic (streptozotocin-treated) diabetic mice. Wounds were injected with human CD34+ or CD34– peripheral blood mononuclear cells or no cells, and analyzed for vascularity and healing at various times thereafter. Treatment with CD34+ enriched cells decreased wound size by 4 days after treatment, accelerated epidermal healing, and rapidly and dramatically accelerated revascularization of the wounds compared to controls. Initially increased vascularization was mediated principally by an increase in vessel diameter, but later, both an increase in vascular size and number were observed. These findings indicate that blood-derived progenitors may have therapeutic potential in the treatment of skin lesions in the setting of diabetes, and give insights into how bone marrow cells exert their effects on neovascularization.

Keywords:
Angiogenesis, Diabetes, Endothelial progenitor, Endothelium, Skin, Stem cell, Wound healing
1.
Adler AI, Neil HA, Manley SE, Holman RR, Turner RC: Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom prospective diabetes study (UKPDS 47). Am Heart J 1999;138:S353–S359.
2.
Akbari CM, Gibbons GW, Habershaw GM, LoGerfo FW, Veves A: The effect of arterial reconstruction on the natural history of diabetic neuropathy. Arch Surg 1997;132:148–152.
3.
Ansel JC, Armstrong CA, Song I, Quinlan KL, Olerud JE, Caughman SW, Bunnett NW: Interactions of the skin and nervous system. J Invest Dermatol Symp Proc 1997;2:23–26.
4.
Aronin N, Leeman SE, Clements RS Jr: Diminished flare response in neuropathic diabetic patients. Comparison of effects of substance P, histamine, and capsaicin. Diabetes 1987;36:1139–1143.
5.
Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM: Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964–967.
6.
Cameron NE, Cotter MA: Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 1997;46(suppl 2):S31–S37.
7.
Colville-Nash PR, Willoughby DA: Growth factors in angiogenesis: Current interest and therapeutic potential. Mol Med Today 1997;3:14–23.
8.
Haegerstrand A, Dalsgaard CJ, Jonzon B, Larsson O, Nilsson J: Calcitonin gene-related peptide stimulates proliferation of human endothelial cells. Proc Natl Acad Sci USA 1990;87:3299–3303.
9.
Harrington C, Zagari MJ, Corea J, Klitenic J: A cost analysis of diabetic lower-extremity ulcers. Diabetes Care 2000;23:1333–1338.
10.
Jaffe EA, Nachman RL, Becker CG, Minick CR: Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973;52:2745–2756.
11.
Kennedy WR, Wendelschafer-Crabb G: Utility of skin biopsy in diabetic neuropathy. Semin Neurol 1996;16:163–171.
12.
Kunjathoor VV, Wilson DL, LeBoeuf RC: Increased atherosclerosis in streptozotocin-induced diabetic mice. J Clin Invest 1996;97:1767–1773.
13.
Lawrence WT, Diegelmann RF: Growth factors in wound healing. Clin Dermatol 1994;12:157–169.
14.
Newman PJ, Berndt MC, Gorski J, White GCD, Lyman S, Paddock C, Muller WA: PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science 1990;247:1219–1222.
15.
Nilsson J, von Euler AM, Dalsgaard CJ: Stimulation of connective tissue cell growth by substance P and substance K. Nature 1985;315:61–63.
16.
Pecoraro RE, Reiber GE, Burgess EM: Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care 1990;13:513–521.
17.
Reiber GE, Pecoraro RE, Koepsell TD: Risk factors for amputation in patients with diabetes mellitus. A case-control study. Ann Intern Med 1992;117:97–105.
18.
Schatteman GC, Hanlon HD, Jiao C, Dodds SG, Christy BA: Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice. J Clin Invest 2000;106:571–578.
19.
Schratzberger P, Schratzberger G, Silver M, Curry C, Kearney M, Magner M, Alroy J, Adelman LS, Weinberg DH, Ropper AH, Isner JM: Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. Nat Med 2000;6:405–413.
20.
Senapati A, Anand P, McGregor GP, Ghatei MA, Thompson RP, Bloom SR: Depletion of neuropeptides during wound healing in rat skin. Neurosci Lett 1986;71:101–105.
21.
Servold SA: Growth factor impact on wound healing. Clin Podiatr Med Surg 1991;8:937–953.
22.
Shi Q, Rafii S, Wu MH, Wijelath ES, Yu C, Ishida A, Fujita Y, Kothari S, Mohle R, Sauvage LR, Moore MA, Storb RF, Hammond WP: Evidence for circulating bone marrow-derived endothelial cells. Blood 1998;92:362–367.
23.
Swift ME, Kleinman HK, DiPietro LA: Impaired wound repair and delayed angiogenesis in aged mice. Lab Invest 1999;79:1479–1487.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.